Recent cases show labs should be wary of issues such as improper relationships, medical necessity, kickbacks, and potential telehealth fraud.
Medical director William G. Finn, MD, discusses key trends, challenges, and opportunities related to the expansion of at-home testing.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Diana W. Bianchi, MD, discusses how NIPT has evolved, key challenges, as well as her team’s research on using these tests to detect cancer.